Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Lunai Bioworks Inc.
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson’s and Rare Epilepsy AI Discovery Collaboration
May 28, 2026
Federal Judge Orders Expedited Discovery to Identify ‘John Doe’ Defendants ‘Naked’ Short-Sellers of Lunai Common Stock
May 22, 2026
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
May 20, 2026
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
May 4, 2026
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
April 15, 2026
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
April 7, 2026
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer’s Therapies with Broad CNS Delivery Applications
March 26, 2026
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
March 19, 2026
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
January 28, 2026
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
January 27, 2026
1
2
Next Page
→